ABSTRACT
The main cause of cardiac valve bioprosthesis dysfunction is mechanical rupture of the cusps consequent upon the development of "fatigue" tensions and calcification of the biologic tissue. The technology of "Bionix" prostheses manufacturing implies prevention of these complications by means of supporting frameworks of variable rigidity (dumping stroke loads) and the use of a calcinosis inhibitor in the process of chemical stabilization. Experimental research confirms the certain effectiveness of such an approach to solving the problem of bioprosthesis durability. Experience in clinical application of biological valves of this series showed that by the 5th postoperative year the stability of good results was 90.0 +/- 2.2%; absence of thromboembolic complications in 93.3 +/- 2.4%, and no need to operate because of dysfunction of the bioprosthesis in 96.6 +/- 2.1%.
Subject(s)
Bioprosthesis , Calcinosis/surgery , Heart Valve Prosthesis , Mitral Valve Stenosis/surgery , Adult , Aged , Animals , Calcinosis/complications , Calcinosis/physiopathology , Equipment Design , Female , Humans , Male , Middle Aged , Mitral Valve/physiopathology , Mitral Valve/surgery , Mitral Valve Stenosis/etiology , Mitral Valve Stenosis/physiopathology , Postoperative Period , Swine , Time Factors , USSRABSTRACT
It has been shown that Bionics prostheses compare very favorably with bioprostheses based on rigid supporting frameworks. The advantages of the above prostheses lie in the fact that the supporting frameworks of changed stiffness used in their modelling possess damping capacities at minute physical loadings, which considerably improves the hydrodynamic characteristics of biovalves.
